Sam-A Pharm. Co., Ltd.
KKRX:00930013,560.00
KRW
-130.00
(-0.95%)
ISIN
KR7009300005
Return %
Stock
S&P 500
1Y
-19.53
14.39
3Y
-13.63
81.42
5Y
-41.04
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Jun Huh
- Full Time Employees
- 310
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Wonju-si South Korea
- IPO Date
- Jul 19, 2000
- Website
- samapharm.co.kr
- Similar Companies
- Business
- Sam-A Pharm. Co., Ltd. is a South Korea-based pharmaceutical company primarily engaged in the research, development, manufacturing, and commercialization of prescription pharmaceuticals, over-the-counter medications, and health functional foods. Founded in 1945 and headquartered in Seoul, South Korea, with primary production and research facilities located in Wonju, Gangwon Province, the company supplies specialized therapeutics to hospitals, clinics, and retail pharmacies across South Korea and selective international markets. The company operates across multiple core therapeutic segments, offering a comprehensive product portfolio that comprises: respiratory and allergic disorder treatments, including leukotriene receptor antagonists (Citus dry syrup, chewable tablets, and capsules), bronchodilator patches (Notemon Patch), and antitussive and expectorant formulas (Hebron-F, Codenal); dermatological preparations, including topical anti-inflammatory corticosteroids and eczema therapies (Lidomex cream and lotion); anti-infective and antibacterial agents, including extended-spectrum penicillin combinations (Camodix) and cephalosporin antibiotics (Cenan dry syrup); gastrointestinal and digestive remedies, including prokinetic agents, antacids, and digestive enzymes; cardiovascular and metabolic disease medications, including antihypertensive, lipid-lowering, and antidiabetic agents; antipyretic, analgesic, and anti-inflammatory formulations (Setofen, Tantum); and pediatric healthcare and nutritional supplements marketed under the Noma brand (Noma Chewable, Noma-F, Noma Gold). Additionally, the company provides contract manufacturing organization (CMO) and contract development and manufacturing organization (CDMO) services for solid oral doses, dry syrups, creams, ointments, and transdermal formulations through its automated EU-GMP- and cGMP-compliant manufacturing facility. In recent developments, Sam-A Pharm. Co., Ltd. has accelerated strategic initiatives to diversify its revenue streams, mitigate therapeutic category concentration risks, and enhance operational efficiency. In 2026, the company announced a comprehensive corporate value enhancement program aimed at stabilizing operating profitability, optimizing capital allocation, and strengthening shareholder returns. On the operational and clinical front, Sam-A Pharm has expanded its research and development pipeline focused on incrementally modified drugs (IMDs) and advanced drug delivery systems (DDS), while establishing open innovation collaborations with domestic and international research institutes and biotechnology partners to co-develop next-generation therapeutic candidates. The company has also reinforced lifecycle management and patent defense for its flagship respiratory formulations, executed distribution and regulatory positioning strategies for its core dermatological brands, and scaled its high-precision CMO business to capitalize on third-party manufacturing demand supported by its PMDA-accredited and EU-GMP-certified production infrastructure.